Stock Rating Upgrade
The Value Trend Rating for Xenon Pharmaceuticals Inc (NASDAQ: XENE) improved recently from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock closed at $42.62 on 4/8/24 after a modest gain of 0.9%. However, below average trading volume at 72% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months but has declined -1.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, XENE is expected to continue to be Value Creation neutral.
Xenon Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Xenon Pharmaceuticals has a very low Appreciation Score of 9 but a very high Power Rating of 86, with the Low Neutral Value Trend Rating the result.
Be the first to comment